08:04 AM EDT, 09/02/2025 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Tuesday that topline data from phase 3 studies of olezarsen showed that the drug candidate significantly reduced fasting triglycerides and acute pancreatitis events in patients with severe hypertriglyceridemia.

Results showed a "statistically significant" 72% placebo-adjusted mean reduction in fasting triglycerides and 85% reduction in acute pancreatitis events, the company said.

Olezarsen also showed a favorable safety and tolerability profile, according to Ionis.

The company said it plans to submit a supplemental new drug application to the US Food and Drug Administration by the end of 2025.

Shares of Ionis were up more than 16% in Tuesday premarket activity.

Price: 49.80, Change: +7.17, Percent Change: +16.81